Empegfilgrastim

Drug Profile

Empegfilgrastim

Alternative Names: BCD-017; Extimia; Metpegfilgrastim

Latest Information Update: 04 Nov 2016

Price : $50

At a glance

  • Originator Biocad
  • Class Chemoprotectants; Granulocyte colony-stimulating factors
  • Mechanism of Action Granulocyte colony stimulating factor stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Neutropenia

Most Recent Events

  • 01 Jun 2016 Launched for Neutropenia (Prevention, Chemotherapy-induced) in Russia, Ukraine and India (SC) before June 2016
  • 01 Oct 2014 Biocad completes a phase III trial for Neutropenia (Prevention) in Russia, Ukraine & India (NCT02104830)
  • 03 Apr 2014 Biocad completes enrolment in its phase III trial for Neutropenia prevention in Russia, Ukraine & India (NCT02104830)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top